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Abstract
Hybridization- and tag-based technologies have been successfully used in Down syndrome to identify genes involved in
various aspects of the pathogenesis. However, these technologies suffer from several limits and drawbacks and, to date,
information about rare, even though relevant, RNA species such as long and small non-coding RNAs, is completely missing.
Indeed, none of published works has still described the whole transcriptional landscape of Down syndrome. Although the
recent advances in high-throughput RNA sequencing have revealed the complexity of transcriptomes, most of them rely on
polyA enrichment protocols, able to detect only a small fraction of total RNA content. On the opposite end, massive-scale
RNA sequencing on rRNA-depleted samples allows the survey of the complete set of coding and non-coding RNA species,
now emerging as novel contributors to pathogenic mechanisms. Hence, in this work we analysed for the first time the
complete transcriptome of human trisomic endothelial progenitor cells to an unprecedented level of resolution and
sensitivity by RNA-sequencing. Our analysis allowed us to detect differential expression of even low expressed genes crucial
for the pathogenesis, to disclose novel regions of active transcription outside yet annotated loci, and to investigate a
plethora of non-polyadenilated long as well as short non coding RNAs. Novel splice isoforms for a large subset of crucial
genes, and novel extended untranslated regions for known genes—possibly novel miRNA targets or regulatory sites for
gene transcription—were also identified in this study. Coupling the rRNA depletion of samples, followed by high-
throughput RNA-sequencing, to the easy availability of these cells renders this approach very feasible for transcriptome
studies, offering the possibility of investigating in-depth blood-related pathological features of Down syndrome, as well as
other genetic disorders.
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Introduction
Expression profiles of thousands of genes in various organs and
cell lines have been successfully determined by using different
methods and approaches such as microarray, serial and cap
analysis of gene expression, and massively parallel signature
sequencing [1–11]. These approaches have led to the identifica-
tion of differentially expressed genes in physiological and
pathological conditions, such as Down syndrome (DS) [12–15],
Alzheimer, Parkinson [16–18] and cardiovascular diseases
[2,8,19,20].
In Down syndrome the dosage imbalance of human chromo-
some 21 (HSA21) genes, and the subsequent global gene
deregulation observed overall the genome [12,21,22], have long
been associated to different aspects of DS pathogenesis. Expression
analyses of DS tissues and mouse models have reported conflicting
results [23,24], showing that HSA21 gene expression greatly varies
across trisomic tissues [14,22]. However, most of published works
has focused on hybridization-based technologies - suffering from
hybridization and cross-hybridization artefacts and offering a
limited dynamic range - or tag-based approaches, suffering for the
ambiguous mapping of their short reads. Hence, to date we
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physiologically relevant, RNA classes such as small coding and
(long-) non-coding RNAs. In addition, there is not yet evidence of
DS-specific splice isoforms for genes crucial in the pathogenesis
and, to date, none of published works has described, in a single
experiment, the complete transcriptional networks in Down
syndrome.
The introduction of next generation sequencing (NGS) technol-
ogies has revealed the complexity of mammalian transcriptomes,
enabling to effectively explore - with an unprecedented throughput
capacity - simple and complex genomes [25–31]. NGS have shown
that mostof nucleotides areexpressed, highlighting that only a small
fraction of all transcribed sequences (less than 2%) is represented by
mRNA [32,33], and that not yet well-characterized RNA species,
such as microRNA recently described in DS [34] as well as small
nucleolar RNA (snoRNA), are emerging as potential factors
contributing to pathological phenotypes [35,36].
In the last years, in order to identify genes contributing to DS
phenotype and to its phenotypic variability, the above-mentioned
standard approaches for gene expression profiling have been
applied to several mouse models with segmental duplications of
DNA segments orthologous to human chromosome 21. Alterna-
tively, transcriptome studies on human DS subjects have been so
far performed on post-mortem tissues and/or fetuses, and few studies
have focused on RNAs isolated from human adult whole blood
samples [12,37–39]. Thus, it would be clinically relevant to
investigate, with an innovative and high-throughput approach,
early gene regulatory mechanisms linked to cardiovascular disease,
cancer and immune disorders linked to DS.
To this purpose, we analysed for the first time the global
transcriptome of human trisomic and euploid endothelial
progenitor cells (EPCs) to an unprecedented level of resolution
and sensitivity by RNA-Seq on a next generation sequencing
platform. By using a selective depletion of abundant rRNA
molecules from samples - followed by the sequencing of strand-
specific cDNA libraries - we were able to measure the effects of
trisomy 21 in a specific cell type affected in DS, and also to
quantify the defect during postnatal development, possibly
correlating gene expression changes to the observed phenotype.
Indeed, literature data and our recent findings strongly indicate
that circulating EPCs, whose levels are linked to tissue regener-
ation, are impaired in DS [12,40–42]. These cells play pivotal role
in the maintenance of endothelium integrity, repair after injury
and postnatal neovascularization and several studies suggest their
use in the clinical setting [43–47]. Moreover, accumulating
evidences indicate a reduced availability, and/or impaired EPC
function in cardiovascular and metabolic diseases [12,45,48–50].
Endothelial dysfunction, angiogenesis suppression and infection
recurrence are hallmarks of DS, and the impairment in the
number and function of circulating progenitors may promote a
wide number of diseases. The massive-scale RNA-Seq and the
easy availability of these cells from affected individuals allow to
shed light on endothelium-related pathological features of DS,
rendering this analysis feasible on a large number of samples.
Results
Strand-oriented libraries preparation and sequencing
The ability, and the power, to measure gene expression in
RNA-Seq experiments is strictly correlated to the number of
sequence reads mapped to transcribed regions in a particular cell/
tissue/organism. In the light of this, for a whole-transcriptome
(WT) analysis we planned both our sequencing strategy and
platform usage (Figure S1).
To this aim, a systematic depletion - from total RNA samples -
of very abundant rRNA molecules (consisting of about 95% of
cellular RNA), was performed. This procedure, coupled with the
massive sequencing on NGS platform, allows to investigate the
entire transcriptional landscape of an organism, offering the
possibility to analyse - within the same experiment - polyA
+
mRNAs, long as well as small coding and non-coding RNA
species. It clearly represents a great opportunity, and a challenge,
compared to the commonly used approaches relying on polyA
+
enrichment of the samples [30–32,51–57].
In addition, since preserving the strandedness is fundamental for
further data analysis and interpretation, we created strand-
oriented libraries (SOLs) for each sample. Indeed, SOLs usage
allows to determine the correct directionality of transcription and
gene orientation (for both annotated and unannotated expressed
regions), thus facilitating the detection of opposing and overlap-
ping transcripts.
In this study, we generated SOLs from rRNA-depleted total
RNAs isolated from human EPCs [7,58] of a female affected from
trisomy 21 and one age- and sex-matched euploid, and sequenced
them to a depth of about 100 million of 50 nt reads per library on
a SOLiD v3 platform (Applied Biosystems).
Mapping strategy and visualization
The sequenced reads were mapped on human genome (hg19)
using RNA-MATE [30]. Mapping strategy and results are
illustrated in Figure S2 and Table S1. Details of the mapping
strategy are given in ‘‘Materials and Methods’’ and File S1.
We noted that filtering reads derived from very abundant
rRNAs molecules (5.8S, 18S, 28S) has a great impact on rRNA-
depleted WT experiments since they still constitute a significant
fraction of total sequenced reads, whereas adapter-filtered reads
represent a negligible amount. However, at least for the purpose of
this work, they can be used as a measure of ribodepletion efficiency
rather than a real measure of interest.
The cyclic alignment implemented in RNA-MATE ensured the
detection of expressed regions from both annotated exons and
junctions from a custom library, also giving the possibility to detect
the expression of previously unannotated regions and to identify
novel combinatorial exon usage for every known locus. The low
extent of antisense mapping of reads (about 0.07% for both
libraries) to splice junctions’ libraries, was used to assess SOLs’
directionality and to tune the mapping parameters. In addition,
most of reads (about 90%) that mapped to the genome and to
junction library were 50 nt in length with few sequence
mismatches. Such results are comparable to those obtained in
analogous studies and constitute an overall measure of the quality
the produced data.
At the end of the alignment strategy three types of reads were
distinguished: uniquely assignable reads (UARs), multiple reads
(MRs) and reads without a specific mapping location (denoted as
unmatched reads; see ‘‘Materials and Methods’’, Figure S2 and
Figure S3). For the sake of simplicity we considered only UARs
and reads mapping on junction library for further analyses. We
noted that discarding MRs - which mainly derive from conserved
domains of gene families and/or common repeats - is likely to
introduce an experimental bias, decreasing the coverage and
reducing the possibility to investigate expressed retrotransposons
and most of highly conserved gene families [26]. However, since a
significant fraction of multiple reads was assigned to UARs
category using a rescue procedure, we reduced the above-
mentioned mapping bias (‘‘Materials and Methods’’ and File S1)
[59].
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(with few mismatches) contribute to about 91% of DS and 86% of
euploid unique reads, and to about 76% and 71% of finally
assigned UARs for DS and euploid, respectively.
We observed, as expected due to the presence of an extra copy
of HSA21 for DS sample, a higher amount of sequenced reads
mapping to this chromosome, with the highest (1.33) DS/euploid
mapped reads ratio than observed for the other chromosomes
(mean ratio 0.9960.05). A similar unbalancing in reads’ mapping
was also observed for the mitochondrial chromosome (chr M)
(ratio=1.23) mainly due to the highly variable number of
mitochondria in a cell, organism and tissue type.
To better elucidate the landscape of gene expression in both
states we classified all mapped reads in the following categories:
reads mapping to 1) annotated RefSeq gene models, 2) intronic
regions, 3) intergenic regions, 4) known RefSeq splice junctions
and 5) novel combinatorial junctions and 6) mitochondrial
genome. The mapping of the categories from 1) to 3) and 6) is
depicted in Figure S4. The analysis of each category is described in
the following sections.
Gene expression quantification
Since we previously described in EPCs isolated from DS
individuals a global deregualtion of gene expression compared to
euploid cells [14], we used RNA-Seq to have a better quantitative
estimate of gene expression from both known genes and previously
uncharacterized expressed regions. To this aim we scored each
locus activity in both trisomic and euploid cells by counting the
number of reads mapping to annotated RefSeq transcripts (release
38) [60]. In particular, for gene loci with a single transcript we
estimated gene expression as the number of UARs mapping to the
entire length of the transcript, whilst for genes with multiple splice
isoforms a measure of global locus activity was obtained summing
the reads mapped to any independent exon (or part of exon) of
each possible transcript (details in File S1). In both cases, the reads
count deriving from reads mapped to the junctions library were
added to each corresponding locus.
The representative RefSeq categories (Human Gene Nomen-
clature Committee, HGNC) [61] comprising all the genes detected
and analyzed in the WT experiment are shown in Figure 1A. In
DS as well as euploid sample, about 92% of detected loci with
evidence of active transcription in circulating progenitors fall in
the mRNA category. Surprisingly, the distribution of mapped
reads per category revealed a 2- to 10-fold enrichment of non-
coding RNAs, particularly snoRNA, in both analyzed samples
(Figure 1B and 1C). Moreover, the distribution of mapped reads
(in terms of genomic positions) showed, as expected, a strong bias
toward regions already annotated as genes in RefSeq: on average,
about 50% of mapped reads fell in such regions. However, we
noted that such percentage is significantly smaller than observed
using polyA
+ enrichment protocols.
The gene expression values of already annotated genes were
measured and expressed as reads per kilobase of transcript (or gene
model) per million mapped reads (RPKM) [55]. Using a threshold
of 0.1 RPKM, we detected a total of 17474 and 16800 RefSeq
genes for DS and euploid EPCs respectively with at least one
mapped read, and 13144 RefSeq genes with evidence of active
transcription common for both trisomic and euploid EPCs.
In particular, due to our interest in investigating gene expression
in the context of DS, we also focused on HSA21 genes. Hence, on
a total of 260 RefSeq annotated HSA21 genes, we detected 148
and 141 genes expressed at levels below the threshold for DS and
euploid EPCs samples, respectively.
All RefSeq genes, whose expression was detected within the
experiment, were further classified according to RPKM values in 5
categories of expression: 1) very low, 2) low, 3) intermediate, 4)
high and 5) very high (Figure 2; see ‘‘Materials and Methods’’).
This categorization revealed us, for both trisomic and euploid
samples, a strong enrichment of snoRNAs in the highest RPKM
categories (these RNAs were about 15% of total genes in category
4, and about 90% in category 5), clearly showing these molecules
are below mRNAs – and if we exclude rRNAs - the second RNA
group for abundance, and they also represent the more expressed
RNA fraction in rRNA-depleted WT experiment.
To visualize in a user-friendly way the gene expression data
derived from reads mapping, we prepared genome-wide, strand-
specific, nucleotide-resolution files for each library corresponding
to the trisomic and euploid states. In particular, these files contain
information about reads mapping to the entire human genome, to
splice junctions and RPKM categories for each analyzed RefSeq
gene (see File S1). These resources represent a very powerful tool
for genetics and genomics studies as they allow to easily investigate
the entire landscape of gene expression alongside public genome
annotations within UCSC Genome Browser [62] as ‘‘custom
tracks’’ (Supplementary files available upon request).
Evidence and quantification of intronic and intergenic
transcription
An intriguing finding of this study was the observation that, in
both DS and euploid libraries, about 50% of all mapped reads
occurred outside the annotated loci, outside the furthest 59 and 39
exons of already known genes, strongly indicating that many
RefSeq genes may require extension or revision. This finding also
suggests that this relevant extent of extra-genic transcription may
possibly account for some of the pathological features observed in
Down syndrome, as well as it is likely to occur for other human
inherited disorders.
Thus, to address the extent of intronic and intergenic
transcription, reads mapping to hg19 in non-RefSeq regions were
divided into three categories: 1) intronic (inR) and 2) intergenic
(igR) regions, and 3) chr M.
In particular, in the trisomic sample, about 8.7 M of sequenced
reads mapped to inRs, 5.9 M into igRs and 2.0 M to chrM, for a
total of 16.6 M of reads mapped to non-RefSeq regions. For the
euploid sample, about 7.3 M of reads mapped to inRs, 5.6 M into
igRs and 1.4 M to chrM for a total of 14.3 M of reads mapped to
non-RefSeq regions (Figure S4).
To identify yet unannotated transcribed regions, potentially
representing novel disease-specific expressed regions, and to better
elucidate the still uncharacterized landscape of gene expression in
trisomic EPCs compared to euploid cells, reads were further
filtered with combined annotations from UCSC ‘‘known genes’’
and Ensembl databases (File S1) [63,64]. We found that in DS
sample about 4.6 M of reads (of which 2 M from chr M and
2.6 M from both intergenic and intronic) were supporting either
UCSC or Ensembl annotation, whilst more interestingly 12 M of
reads were still mapped to unannotated regions. In the euploid
sample, about 3.9 M (of which 1.4 M from chr M and 2.5 M from
both intergenic and intronic) supported either the annotations,
whilst 10.4 M of reads still mapped to unannotated regions. We
also observed that most UCSC and Ensembl annotations covered
about 98% of the reads mapping on chr M, about 30% of
intergenic and about 10% of intronic regions, for both samples.
Finally, the reads mapping to yet unannotated regions, from
both DS and euploid samples were pooled together and used to
predict candidate novel intronic and intergenic transcriptionally
active regions (inTARs and igTARs, respectively) - possibly
rRNA-Depleted Transcriptome in Down Syndrome
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models (definitions are given in File S1).
To this purpose, we noticed that 4.2 M of mapped reads in DS
and 3.9 M in euploid - assigned to intergenic unannotated regions
- spanned across 4.9610
9 bp (considering both strands), and
7.8 M of mapped reads in DS and 6.5 M in euploid - assigned to
unannotated intronic regions - spanned across 1610
9 bp (consid-
ering both strands). The size of, such huge, unannotated regions
do not allow to easily identify the presence of significant signal (i.e
density of reads mapping together) from the background noise,
resembling the search of a needle in a haystack. Therefore, ad hoc
refinement procedure with W=500 and T=30 (described in
‘‘Refinement of non-RefSeq loci’’) was used to automatically
extract reads’ dense transcriptionally active regions in a compu-
tationally fast way. The refinement procedure, applied on the
pooled samples, allowed us to define 21804 igTARs (spanning
across about 17 Mb) in which for both samples mapped about
1.8 M of sequenced reads (about 45% of unannotated intergenic
reads). In a similar way, we defined 99030 inTARs (spanning
across about 80 Mb) in which were mapped about 4.1 M and
3.7 M of reads for DS and euploid, respectively (more than 55% of
unannotated intronic reads for both samples). All regions were
annotated in a BED format and the expression levels of both
inTARs and igTARs were then measured for each sample.
Since not yet annotated TARs may be relevant for DS
pathogenesis, we focused on the quantitative evaluation of these
regions. The analysis revealed that 21648 igTARS and 98156
inTARs were transcriptionally active in DS progenitor cells,
whereas 21608 igTARS and 97709 inTARs were active in the
euploid state. Of these, 21460 igTARs were regions of active
Figure 1. RefSeq categories and reads distribution. Distribution of the abundance of the RefSeq categories (HGNC) in the observed actively
transcribed loci of the two states (A); Distribution of the UARs across the distinct RefSeq categories. DS (B) and euploid (C). The ‘‘other’’ category,
marked with asterisk, include less represented RNAs (pseudogenes, microRNA, snRNA, scRNA, antisense, vault and RNAse) according to HGNC.
Percentages are shown in the pie chart.
doi:10.1371/journal.pone.0018493.g001
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respectively DS and euploid specific. Similarly, we identified
96864 inTARs common to both samples, with 1092 and 745
regions DS and euploid specific, respectively.
A random selection of a small subset of newly identified TARs
underwent manual curation for further analysis. Particularly, we
noted that many highly expressed unannotated regions felt in large
repeats family (RepeatMasker based on RepBase library),
comprising short - which include Alu family - and long interspersed
nuclear elements (SINE and LINE), spanning overall the human
genome, and also RNA repeats (such as SSU-rRNA family).
However, an accurate estimate of the expression within such
regions is strongly biased in both samples due to the multiple
localization of these regions alongside the human genome, and
thus further focused studies are needed in order to better address
the extent of expression of such repeats families.
In addition, we also scanned a subset of inTARs and igTARs for
the presence of putative open reading frames (ORFs). The analysis
revealed that a high fraction of these newly identified TARs, both
intronic and intergenic contain ORFs longest than 200 bp. In
particular, some inTARs conserved the correct frame of the gene
they are located within, suggesting these are likely to represent
alternative exons. On the other hand, it has been observed that a
subset of analyzed igTARs (150–250 bp in length) did not show
any ORF, suggesting they may represent novel small and long
non-coding RNAs.
However, these preliminary findings strongly suggest these
newly identified regions of active transcription require both further
experimental validations - and also computational efforts - in order
to address in a genome-wide fashion whether they represent novel
genes - and/or exons of already known genes- and novel short (or
long) intergenic transcripts, and whether the differential expression
of these expressed extragenic regions may be linked at some extent
to observed DS phenotypes.
Independently, we also studied the transcriptional activity in
close proximity to 39 and 59 UTRs of RefSeq loci, in order to
understand whether these regions could possibly represent
extensions of already annotated genes. Particularly, we focused
on expressed regions using a user-defined window 150 bp in
length, located both upstream 59 UTRs and downstream 39
UTRs. We found 3600 and 2948 candidate genes showing a clear
evidence of an extended 39 UTR in DS and euploid samples,
respectively (example in Figure 3A). Of these, 1868 extended
regions were common to both samples, giving a strongest
evidence for the refinement of untranslated regions of these
RefSeq loci. We believe that state-specific extended UTRs
(specifically those expressed in DS progenitor cells) may be
important for gene expression regulation and/or for mRNA
Figure 2. Comparison of RPKM content for RefSeq genes. Distribution of RefSeq categories (according to HGNC) within each class of RPKM.
doi:10.1371/journal.pone.0018493.g002
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pathological features. More interestingly, we observed that most
of newly-defined or extended 39UTRs contain putative novel
miRNA binding sites (data not shown), characteristic of 39UTRs
of annotated transcripts, suggesting these regions may potentially
contribute to microRNA-mediated regulation of these transcripts.
This finding is crucial for understanding putative novel
mechanisms of regulation for genes already known to be involved
in DS pathogenesis, and may also be helpful to identify novel
candidates in the trisomy 21.
Finally, for 59 UTRs we found a lower number of candidate
genes (1491 and 1280 for DS and euploid, respectively) possibly
needing annotation revision, which indicates that current
annotations are more biased toward the 39 UTRs of expressed
transcripts (example in Figure 3B).
Survey on the alternative splicing
Massive-scale RNA sequencing data, other than identifying
differential expression of genes in a disease, are useful to human
genetics in what they can be used to investigate alternative
splicing, also discovering novel splice isoforms for crucial genes.
For instance, identifying sequence reads that span exon-exon
junctions could help to define exon usage and alternative splicing
(although reconstructing entire transcripts will be challenging,
particularly with short reads and it will require a very high
coverage and the use of paired-end reads to achieve a good
accuracy).
However, to illustrate the great potential of these data for
studying both canonical and alternative splicing in the context of
Down syndrome, we performed a preliminary analysis to identify
reads that span exon-exon junctions. We detected a total of 92939
splice junctions in DS sample and 80200 in euploid; of these,
64115 and 56621 (DS and euploid, respectively) mapped with at
least 3 sequenced reads, whilst 48604 and 43308 (DS and euploid,
respectively) mapped with at least 5 sequenced reads (Table S2).
In addition, as expected for large-scale RNA-Seq data, we
found evidence of several alternative splicing events (ASEs) in
known RefSeq genes with a user-defined threshold of 3 and 5
mapped reads. To achieve a highest reliability of these data, we
considered a user-defined threshold of at least 5 mapped reads as
informative for ASEs (Figure S5). By using this approach, we
found that 1621 splice junctions in DS and 1783 in euploid were
representative of ASEs (i.e either multiple donor or multiple
acceptor junctions; details in ‘‘Materials and Methods’’).
In order to identify ASEs specific of DS progenitor cells,
avoiding a ‘‘threshold-dependent’’ exclusion of any given junction
(i.e of junctions with a number of mapped reads slightly below the
chosen threshold), we marked as ‘‘sample-specific’’ only junctions
without any mapping in the euploid state (and viceversa). By using
this procedure, we found that about 18% of all ASEs detected in
each sample were sample specific. Indeed, we identified 294 DS-
specific and 323 euploid-specific alternative splice events (Figure
S5 and Table S2). Of these, 135 junctions for DS and 229 for
euploid (45.9% and 70.9% of total state-specific ASEs, respective-
Figure 3. Evidence of 39 and 59 UTRs gene extensions. Illustration of 39 (A) and 59 (B) extended UTRs that are present in both samples.
doi:10.1371/journal.pone.0018493.g003
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Ensembl), thus representing good candidates for further analyses
aimed to fully characterize novel disease-specific isoforms within
DS isolated EPCs. Examples of genes with evidence of sample
specific splicing are depicted in Figure 4.
Interestingly, this analysis showed evidence of a DS-specific
splice junction (transcript variant NM_130436.2; proteinID
Q13627-2) in a crucial HSA21 gene involved in DS pathogenesis,
namely DYRK1A [65]. For all mentioned cases, sequence reads
supporting evidence of alternative splicing will be helpful for
further detailed analyses aimed to resolve, if any, possible exon-
annotation conflicts.
In the context of the syndrome, we also observed that some
interesting genes, involved in the immune response and angio-
genesis pathways - and previously shown to be deregulated in DS
EPCs [12] - had evidence of yet unannotated sample-specific
isoforms. Further analyses are needed to address whether these
isoforms may play a role in DS pathogenesis.
The transcriptome complexity of DS beyond the rRNA
NGS has revealed the evidence of previously not well,
characterized - or completely uncharacterized - RNA molecules,
emerging as crucial regulators of many biological processes and for
their potential link to human diseases. Small RNAs, including
miRNAs, regulators of gene expression involved in various cellular
processes, as well as small nucleolar RNAs (snoRNAs) - central to
ribosome maturation and guides for site-specific modification of
rRNAs - are acquiring greater attention for their involvement in
human inherited disorders [35,36]. In addition, long as well as
short non coding RNAs, whose functional significance is still
debated, and other classes of coding and non coding RNAs have
been also described at transcriptional start sites, splice sites or in
large intergenic regions [66–68].
In our experiment, not limited to the annotated polyA
+ mRNA
fraction, we detected and quantified active transcription in both
human trisomic and euploid isolated EPCs from snoRNAs, small
nuclear RNA (snRNA), miRNAs and other non-coding RNA,
including lincRNAs.
In particular, we focused on UARs mapping to annotated
snoRNAs, for which, as above described for the RefSeq genes, we
measured gene expression as RPKM. Evidence of active
transcription from 289 snoRNA (171 C/D box snoRNAs alias
SNORD genes, 95 H/ACA box snoRNAs alias SNORA genes
and 23 Cajal body-specific scaRNAs) was observed for DS cells,
and the expression of 289 snoRNAs (173 C/D box, 93 H/ACA
box and 23 Cajal body-specific scaRNAs) was detected in the
euploid state. For both analysed samples, we observed a
significantly strong increase (about 170-fold) in mean RPKM
values for this class of RNAs compared to ploy-A
+ transcripts
(Figure 2).
In addition, we independently selected snoRNA belonging to
‘‘Very high’’ and ‘‘High’’ RPKM categories, which represent
almost the totality of snoRNAs, and observed that the vast
majority of these localize within the introns of RefSeq genes
(namely host genes). Then, we analyzed the expression level, in
terms of RPKM, of their related host genes. Table S3 shows the
occurrence of each RPKM category of the host genes for two
classes of snoRNAs, both in DS and euploid samples. We noted
that 221 highly-expressed snoRNAs common to both states (76%
of the total), preferentially - if not exclusively - mapped within
intronic regions of highly-expressed genes (Figure 5A). More
interestingly, none of highly-expressed snoRNA localized within
Figure 4. State-specific alternative splicing. Example of sample-specific alternative splicing events with T1=5. Reliable junctions are highlighted
in light red for both cases (DS in panel A and euploid in panel B). Junctions highlighted in light grey are below the threshold. State-specific junctions
are those not showing any hit in the other sample.
doi:10.1371/journal.pone.0018493.g004
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any evidence of expression (Table S3), suggesting this class of small
RNAs is preferentially located within euchromatic regions of very
active transcription.
Moreover, since it has been recently shown that snoRNAs can
be processed into snoRNA-derived RNAs (sdRNAs) [67], we
analysed our WT data to address these specific features. Hence, we
interestingly observed, as recently shown by Langenberger and
colleagues [69], a correlation between reads’ mapping pattern and
snoRNAs processing steps, and possibly with their structural - and
thus functional - properties (Figure 5B). As there depicted,
snoRNAs clearly show specific block patterns with a characteristic
reads coverage distribution. The particular enrichment of reads
mapping to specific snoRNA sites is very likely to be correlated to
its processing steps. A similar correlation with the secondary
structure processing of non coding RNAs, even though at a lower
extent due to RNA extraction protocol and library construction,
was also observed for miRNAs (data not shown). However, these
findings highlight the great potential of RNA-Seq data, deriving
from ribosomal RNA-depleted samples rather than polyA
+
enrichment procedure, for a better functional classification and
the identification of novel non-coding RNAs.
Furthermore, a significant differential expression (DE) of
snoRNAs in human trisomic EPCs (compared to euploid) was
also observed (Table S4). In particular, 46 C/D box snoRNAs (3
up- and 43 down-regulated), 31 H/ACA box (9 up- and 22 down-
regulated) and 9 Cajal body-specific scaRNAs (2 up- and 7 down-
regulated) were differentially expressed in DS compared to euploid
cells. Interestingly, we noted that the gene with the highest
expression of HSA21 was a member of H/ACA box, SNORA80,
which showed a strong evidence of DE in the trisomic cells.
Similarly, the expression of annotated RefSeq miRNA encoding
genes was also measured. Expression from about 180 of them was
detected, although about 20% of them had a small number of
mapped reads in both samples. A significant DE in DS isolated
progenitors compared to euploid, was also observed for a small
subset of them (15 miRNA with a significant number of mapped
reads; data not shown).
Finally, we also measured the expression from annotated
lincRNAs (Homo sapiens GRCh37, Ensembl 58). Since the average
length of these regions was significantly higher than RefSeq genes,
on average RPKM values were smaller. However, a significant
expression was detected for 1335 and 1269 regions for DS and
euploid sample respectively, even though a subset of them
completely or partially overlapped with RefSeq genes or repeated
regions. After removing them from further analyses, we observed a
significant differential expression in the trisomic state for 45
lincRNAs (Figure S6).
Differentially expressed genes in human trisomy 21
Given the quantitative nature of our analysis, we used UARs
and reads mapping to junction library to detect DE genes between
the trisomic and euploid states.
In particular, we observed 1629 DE genes marked as ‘‘good’’
(about 12% of total detected genes in both samples), 158 as
‘‘strong’’, 54 ‘‘acceptable’’, whilst a large fraction (1827 genes)
showed weak evidence of DE in the trisomic state since it did not
pass the 1.5 fold-change cut-off. We selected only DE genes
marked ‘‘strong’’ and ‘‘good’’ for further analyses (definitions are
given in ‘‘Materials and Methods’’).
Of these 1787 genes showing evidence of differential expression
between samples, 956 were up-regulated and 831 down-regulated
in DS endothelial progenitors (Figure 6A). In contrast, about 75%
of RefSeq annotated genes did not show any evidence of DE in the
syndrome (Figure 6B). We also observed that 55 HSA21 genes -
out of the 132 expressed in both DS and euploid cells - were DE in
the trisomic state and, more interestingly, most of them (50 genes
out of 55 HSA21 genes differentially expressed in DS) were up-
regulated. Quantitative Real-Time PCR was used to validate the
expression values in 24 actively transcribed loci per sample,
confirming the evidence of DE also for genes marked as ‘‘weak’’ or
‘‘no change’’ (Figure S7 and Table S5).
The list of DE genes was then analyzed by using PANTHER
(Protein ANalysis THrough Evolutionary Relationships) Classifi-
cation System [70] in order to establish the occurrence of more
representative deregulated pathways in the syndrome. The
analysis revealed a particular enrichment for inflammation,
angiogenesis, integrin and Wnt signaling pathways (Figure 7A).
In addition, to highlight the most relevant biological processes
possibly contributing to DS phenotypes previously observed in
EPCs [12], we used a newly developed application for Gene
Ontology (GO) analysis on RNA-seq data, namely GO-Seq [71].
By using the selection of genes DE within DS progenitor cells, we
observed a particular enrichment for GO terms related to immune
and inflammatory responses, cell adhesion and chemokine/
cytokine receptor activities (Figure 7B). These GO terms are in
agreement with the independent analysis of enriched gene
pathways performed with PANTHER. Taken together these
findings, which confirm independent results deriving from a
genome-wide microarray analysis on EPCs isolated from young
DS [12], strongly suggest that these biological processes, and the
related genes, require much attention to further address their
involvement in DS vascular and immune-related phenotypes.
Furthermore, in order to understand whether the newly
identified igTARs and inTARs were differentially expressed
within the syndrome, a similar approach was also used. In
particular, we found that 44, out of the total 21804 igTARs
identified in DS cells, were classified as strong DE regions, 1792
showed good evidence of DE, and 130 were classified as
acceptable DE. For what concerns the inTARs, among the
99030 defined regions, we found 48 of them with strong evidences
of DE in DS sample, 3173 with good and 720 defined as
acceptable evidence of DE. In both cases, we noticed that the
observed fold changes were sufficiently large, hence the threshold
effect was negligible. Results are shown in Figure S8. These results
suggest a possible involvement of such expressed regions in the
pathogenesis of this syndrome, indicating that some yet unknown
genetic determinants may be responsible of, or contribute to, the
wide spectrum of DS pathological phenotypes.
Discussion
RNA-Seq experiments revealed that the transcriptional land-
scape in higher eukaryotes is much more complex than previously
anticipated, with a high proportion of transcripts originating from
intergenic regions, referred to as ‘‘dark matter’’ [72,73], thought to
be transcriptionally silent or antisense to genes [33]. Previously
Figure 5. snoRNAs expression and mapping block patterns. (A) illustrates the percentage of snoRNAs host genes (SHG) vs non host genes
(nSHG) within each RPKM category for both DS and euploid samples. (B) is a schematic representation of maximum coverage of few examples of
snoRNAs, showing a characteristic mapping block pattern. Black and red numbers refer to DS and euploid maximum coverage, respectively.
doi:10.1371/journal.pone.0018493.g005
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18493Figure 6. Differentially expressed RefSeq genes in human trisomy 21. (A) Standard MA-plot of the normalized global observed counts per
each RefSeq gene. (B) shows the percentage of RefSeq genes classified as strong, good, acceptable evidence of DE with respect to those not showing
any statistical evidence.
doi:10.1371/journal.pone.0018493.g006
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enrichment started to shed light on the transcriptional complexity
in humans and other organisms [27–31]. Nonetheless, the
information revealed by using this approach could only detect a
fraction of the total RNA content, representing the tip of the
iceberg. In contrast, in our study we show the clear advantage of
the whole trasncriptome analysis of rRNA-depleted samples for
studying Down syndrome. Hence, our approach offers the
possibility to detect previously not well-characterised - or
completely uncharacterized - non-coding RNA, such as snoRNAs,
miRNAs and others, emerging as novel candidates for their
possible contribution to the pathogenesis of different human
disorders [34–36]. Coupling the ribodepletion procedure of
samples followed by massive-scale RNA sequencing provides
new intriguing opportunities to better understand the underlying
molecular bases of complex phenotypes, such as herein described
for Down syndrome.
In contrast, in the last years, most of studies mainly focused on
hybridization- and tag-based expression profiling on post-mortem
DS tissues and fetuses, with only few of them considering adult
whole blood samples as a good source of RNA to address these
aspects [37–39]. Since angiogenesis’ suppression, endothelial
dysfunction and infection recurrence are hallmarks of DS, and
several studies suggest the use of endothelial progenitors -
previously shown to be impaired in DS [12] - in the clinical
setting [43–47], these cells represent an optimal source for
studying blood-related DS pathological features. Therefore, the
possibility to investigate in a genome-wide scale and easy-
accessible non-invasive manner - early gene regulatory mecha-
nisms responsible of cardiovascular disease, cancer and immune
disorders in DS, would be of great clinical interest. Hence, our
study was accurately designed to investigate these issues.
The analysis of the whole transcriptome of DS-isolated EPCs
allowed us to detect differential expression - compared to the
euploid sample - of even low expressed genes in immune and
inflammatory pathways, crucial for DS pathogenesis, showing the
great potential of RNA-Seq to detect even subtle changes in gene
expression. Clearly, we are aware that we cannot conclusively
attribute to trisomy 21 all the changes in transcript levels found
within this single case-control study since RNA-Seq decreases the
experimental noise, but cannot reduce the individual variability. In
order to separate the confounding effect due to the individual
variability from the effect related to DS condition, a larger number
of biological replicates - for each condition - should be considered.
However, in this case, most of gene expression changes identified
in the present work confirmed other data derived from previous
independent studies performed on the same specific cell type in
more DS and euploid samples [12].
At the same time we also disclosed novel regions of active
transcription falling outside annotated loci, with strong evidence of
DE within DS progenitor cells. In addition, our work revealed a
wide spectrum of not yet well-characterized non-coding RNAs
(particularly snoRNAs) with evidence of differential expression,
some of them localized on HSA21 and shown to be over-expressed
in DS cells, possibly accounting for some of the observed
angiogenesis- and immune-related DS phenotypes.
Moreover, our approach allowed us to identify novel DS-
specific splicing isoforms for a large subset of genes, even
belonging to crucial pathways involved in DS pathogenesis (i.e.
DYRK1A) [65]. Alternative splicing is currently known to generate
either novel transcripts – possibly encoding novel domains – or to
have regulatory roles through balancing levels of those mRNAs
encoding functional proteins [74] and, very recently, it has been
highlighted the power of RNA-Seq in detecting splicing differences
in brain regions of individuals affected by Alzheimer’s disease [75].
In addition, low-expressed transcripts, subtle changes in the
expression of both known and, more interestingly, yet unannotated
transcripts, were also investigated. It should be noted that a
fundamental aspect of gene expression regulation, emerging as a
crucial issue for inherited disorders and cancer in humans, is the
identification of cis- and trans-acting regulatory regions within 59
and 39 UTRs of genes. To this aim, the present study shows the
great potential of RNA-seq towards the identification of novel
putative extended UTRs for already known genes, possibly
representing novel miRNA targets or regulatory sites for gene
transcription, and to our knowledge this is the first paper
describing the complete transcriptome of HSA21 trisomic
endothelial progenitor cells.
On the other hand, it is clear that the high extent of complexity,
not completely detected by commonly used approaches, opens
several new challenges either from computational and experimental
point of view, not easily solvable within a single study. For instance,
the much higher level of mapping disclosed, and then measured,
into unannotated TARs, requires suitable procedures to build
appropriatenovelgenemodels.Furtherstudieswillbethenrequired
to combine information from annotated genes, extended 39 and 59 -
and exon boundaries - with thosearising from igTARsand inTARs.
A possible way to cope with this problem could be to build-up
putativegene modelsandassessthembyusingdata-drivenlibraryof
junctions and iteratively repeat the mapping in a similar way as
proposed by TopHat [76]. Another challenge to face is the
reconstruction, and thus the further quantification, of multiple
isoforms of a transcript, including those arising unannotated TARs
or coming from revised gene models, in a statistical rigorous way.
Clearly, as occurs for any data-driven procedure, such
approaches are likely to require very high coverage, a large
number of samples and the integration with different type of
biological information and data in order to be robust.
In conclusion, although with the limitation for the number of
analyzed samples, we have shown the great potential of
performing whole transcriptome RNA sequencing using ribosom-
al-depleted samples from a technical, technological and bioinfor-
matics point of view. We believe the above-described procedures
may represent a useful guideline even for larger, and more
statistically significant, case-control studies based on RNA-Seq.
Since transcriptome profiling represents a powerful tool for the
functional analysis of EPCs in health and disease [77], coupling
this innovative technological approach, as shown herein within the
context of Down syndrome, to the easy availability of circulating
progenitor cells from blood samples, render this kind of analysis
very feasible for large-scale studies of transcriptome in both
physiological and pathological states.
Materials and Methods
Total RNA isolation and ribodepletion
Cells were isolated as described in [7] from peripheral blood
samples of DS and euploid donors recruited at the Second
Figure 7. Pathway of differentially expressed RefSeq genes in DS sample. Bar graph representation of differentially expressed genes in DS
vs euploid samples. (A) More enriched gene pathways are represented. The number of total DE RefSeq genes is also depicted. (B) Pie chart showing
the percentages of representative GO terms (biological processes) enriched in DE genes in the DS sample compared to euploid.
doi:10.1371/journal.pone.0018493.g007
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the ethics’ review board of the ‘‘Monaldi Hospital’’, Second
University of Naples. Written informed consent was obtained from
individuals involved in this study according to the principles
expressed in the Declaration of Helsinki.
Briefly, total mononuclear cells were isolated by density gradient
centrifugation of peripheral blood samples on Histopaque-1077
(Sigma). Cells were washed twice with PBS, plated on culture
dishes pre-coated with gelatin and fibronectin and maintained in
endothelial growth medium-2 (EGM2; Cell Systems). Cells were
cultured at 37uC with 5% CO2 in a humidified atmosphere. After
four days, non-adherent cells were removed and adherent cells
were collected for RNA isolation.
Total RNA was isolated from endothelial progenitor cells as
described [7]. Integrity and quantity of RNA was evaluated by
Experion (Biorad), following the manufacturer’s instructions.
Ribosomal RNA depletion was performed on 10 mg of isolated
total RNA by using magnetic beads (RiboMinus
TM Eukaryote Kit
for RNA-Seq, Invitrogen) according to the manufacturer’s
protocol (see for technical details File S1). 10 mg of total RNA
were incubated at 72uC for 5 min to allow a complete
denaturation for efficient hybridization to single-stranded eukary-
ote rRNA sequence-specific 59-biotin labeled oligonucleotide
probes (targeted against 5S, 5.8S, 18S and 28S human rRNAs)
containing locked nucleic acids (LNA) at specific positions. Then,
streptavidin-coated RiboMinus
TM Magnetic Beads were used to
capture rRNA-probes complexes to be further discarded form
total RNA samples. The efficiency of rRNA depletion was
evaluated on the Experion. Resulting RNA was successfully
fragmented with RNase III and, after cleanup with RiboMinus
TM
Concentration Module (Invitrogen) according to the manufactur-
er’s protocol, resulting fragmented samples were quantified on the
Qubit Fluorometer (Invitrogen). The appropriate size distribution
of fragmented RNA was finally evaluated on the Experion. The
experimental procedure used in this work is illustrated in Figure
S1.
Stand-oriented cDNA library preparation
100 ng of the fragmented RNA samples were hybridized and
ligated to double stranded oligonucleotides adapter suited for the
59 SOLiD System sequencing (details in File S1). Reverse
transcription was performed using ArrayScript
TM Reverse Tran-
scriptase. Purified cDNA samples were denatured on 6% TBE-
Urea gel, and size selection (150–250 bp) was performed. PCR
amplification on gel slices was then performed using AmpliTaqH
DNA Polymerase, and yield of purified PCR products was assessed
on the Qubit Fluorometer and NanoDrop spectrophotometer
(Invitrogen). Size distribution of cDNA libraries was evaluated on
the Experion.
SOLiD sequencing
We drove 500 pg of each library onto 1-mm-diameter beads
using emulsion PCR, according to the SOLiD
TM Whole
Transcriptome Analysis Kit (Applied Biosystems). Libraries were
sequenced using the Applied Biosystems SOLiD sequencing, as
50-mers. We sequenced ,200,000,000 (100 M for each sample,
euploid and DS) beads using ‘sequencing by ligation’ chemistry on
a SOLiD sequencer version 3 (Applied Biosystems). Approximate-
ly 97% of beads deposited onto the slice generated good-quality
sequence reads 50 nt in length (Figure S2 and Table S1).
SOLiD processed files have been submitted to the Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
repository (accession n. GSE27443).
Quantitative Real-Time for RNA-Seq validation
Quantitive Real-Time PCRs were performed on the same
euploid and DS rRNA-depleted samples that underwent library
construction and further sequencing on the SOLiD platform.
Amplification reaction mix contained 16 SYBR Green PCR
master mix (Applied Biosystems), 160 nM of each primer and
about 50 ng of cDNA (RNA equivalent) as template. PCR
conditions were 95uC for 10 min followed by 40 cycles of 95uC
30 sec, 60uC 30 sec and 72uC 30 sec. Melting curves were
generated after amplification. Data were collected using the
7900HT Fast real time PCR system (Applied Biosystems); each
assay for each of the 24 analysed genes (Figure S7) was performed
in duplicate in both rRNA-depleted samples. Primers were
designed using Oligo 4.0-s. The relative gene expression was
calculated using the 2
2DDCt method [78].
Mapping strategy and data visualization
The whole mapping strategy is illustrated in Figure S2 and
consists in several steps. First, the total reads produced were
filtered out accordingly to quality values, secondly, those reads that
mapped to the adapters and to the ribosomal sequences were
further removed, thirdly RNA-MATE software [59] version 1.1
was used to map the usable reads either to the genome and to a
custom-designed library of exon-junction sequences, (see File S1).
RNA-MATE is an open source software specifically designed to
map RNA-Seq data generated from the SOLiD system. It works
cyclically. At each cycle it attempts to map usable reads first to the
reference genome and subsequently to the junctions’ library. At
the end of each cycle, reads failed to map to the genome or to the
junctions library were left-end trimmed using a pre-defined lengths
schema.
RNA-MATE allows a user to control the number of mismatches
tolerated for each cycle, however it does not incorporate the
possibility of mapping gaps, reducing the possibility of locating
reads with small indel. Moreover, it requires the pre-construction
of a junctions library limiting the possibility of identifying de-novo
junctions. However, the assessment and the correct interpretation
of mapping strategies that are junctions model free has not been
completely elucidated and good performance are obtained only at
the price of a much higher coverage. Moreover, tail-end trimming
the reads at each cycle allows either to cope with the behaviour of
the quality values (that are usually worst in last bases of the reads)
and to partially handle the presence of novel splicing junctions
allowing to map the right side of the read.
By default, RNA-MATE allows to directly assign multiple reads
with a single ‘‘best hit’’ to that specific position. In our pipeline, all
remaining multiple reads (with at most 10 mapping positions)
underwent the rescue procedure with default parameters.
At the end of the alignment procedure three types of reads were
identified: UARs, MRs and unmapped reads (see File S1 for
definitions).
Annotation and quantification of RefSeq transcriptional
events
Given the results of the alignment, first we performed a within
sample analysis aimed to extract and characterize the activity of
both states independently, then we provided a cross-comparison
between trisomic and euploid cells aimed to detect differences in
term of gene expression.
In order to provide a quantitative estimate of gene expressions
in both trisomic and euploid cells, we considered genes in the
ReqSeq annotation. However we suitably revised the annotation
to remove ambiguities due to overlapping genes, see File S1 for
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elements (i.e., exons or part of them) in a BED format
corresponding to 21122 uniquely identified (and non redundant)
RefSeq genes or group/family of RefSeq genes.
For each gene in the RefSeq annotation a preliminary estimate
of the global expression was obtained by computing the number of
UARs starting in all the annotated elements (i.e., exons or part of
exons) corresponding to the same gene. Then, the final expression
value was corrected by adding to each specific locus the read counts
derived from the splice junctions. Additionally, an exon by exon
usage map and the corresponding reads counts was provided in
order to facilitate isoforms identification.
To account for transcripts of different lengths when selecting
active genes, the gene expression counts values of annotated loci
were converted in RPKM [55]. For each sample, only loci with
RMKM.0.1 were considered detected.
Expressed genes in both samples were further classified
according to RPKM distributions in 5 categories: 1) very low
expression, 2) low expression, 3) intermediate, 4) high and 5) very
high expression (Figure 2 and details in File S1).
The analysis of RefSeq loci was also aimed to detect a particular
enrichment in 39 (or 59) UTRs (see File S1).
Identification of alternative splicing events
We inferred the evidence of multiple isoforms within each
annotated gene on the basis of the reads that mapped to the
splicing junctions and we suggested the presence of novel isoforms
from the type of junction mapped (i.e., junctions annotated in
some database such that RefSeq, UCSC or Ensembl or novel
combinatorial junctions). In particular, we considered as alterna-
tive splicing marks either the multiple donors or the multiple
acceptor (or both) junctions (see File S1 for definition).
For the sake of simplicity to reduce the effect of the random
matching, a junction was considered reliable if there were at least
T1 reads mapped on it. Then the identification proceeded as
follows. First, for each sample, we retrieved all the reliable
junctions and, among them we selected those containing either
multiple donors or multiple acceptors. Then, RefSeq genes
containing such junctions were detected. Such genes constitute
an initial list of candidates to the presence of multiple splicing
isoforms. The lists can be further filtered using information arising
from exon by exon map usage to remove mapping artefacts.
Secondly, the two samples were cross-compared as follows: the
spliced junctions common to both samples were identified then, for
each sample, a list of candidate sample specific junctions was
obtained. To remove the effect of the user specific threshold T1,
each list was subsequently filtered, by removing those junctions
that received any number of hits in the other sample.
Finally, since each junction was also classified as RefSeq
junction, UCSC, Ensembl junction or as putative new junction
accordingly to if it was annotated in the corresponding database or
it was a results of a pure combinatorial process, we use such
information to detect those genes containing putative new
junctions that are candidate to show novel (unannotated) isoforms.
Refinement of non-RefSeq loci
Given the RefSeq annotation we defined and annotated on each
strand on the genome igRs and inRs (File S1) to cover all the
genome. The annotation was performed independently on each
strand and regions were labelled, enumerated and described in a
BED file. The regions were quantified in each sample to provide a
measure of the overall mapping in non RefSeq regions. In order to
quantify the strength of the signal in the truly unannotated regions,
both igR and inR were filtered on the basis of the UCSC and
Ensembl Annotation (see File S1).
Remaining regions were re-labelled and enumerated. The reads
count was repeated on both samples. For comparative purposes
and to assess the consistency of UCSC and Ensembl databases, the
reads count was also performed on the UCSC and Ensembl
Annotation filtered by the RefSeq annotation.
Subsequently, to more precisely determine novel active regions,
each unannotated genomic region (either igR and inR) that
showed presence of signal (i.e., mapped reads) underwent an ad-
hoc refinement procedure. The refinement procedure is aimed to
more precisely define the approximate location of the active
regions within the unannotated regions (i.e., to identify igTARs
and inTARs, where there is a concentration of reads, removing
those regions or part of regions which showed sparse or no signal
at all).
The refinement procedure was performed either on each
samples independently - to determine sample specific annotations
(data not shown) - and by pooling together the two samples in
order to determine a set of unannotated active regions, igTARs
and inTARs, on which trisomic and euploid cells can be
compared. The reads count was finally repeated for each sample.
Statistical tests for differential expression
In order to detect DE between trisomic and euploid states, we
first compared the two samples at RefSeq level, then we compared
the previously identified un-annotated intergenics and intronic
regions.
Statistical significance has been inferred from the total observed
reads count in each locus combining together a bunch of tests,
namely DEGseq [79], DESeq [80] and edgeR [81] for which R-
packages are available under Bioconductor (www.bioconductor.
org/packages/2.7). Such tests are based on slightly different
assumptions that usually produce a different level of stringency -
and sometime different results - when applied to small sample
experiments. However, all of them are particularly suited for
RNA-Seq data, hence they were independently applied to the
dataset. For each locus we compute a p-value and its correspond-
ing adjusted p-value or q-value to detect significant change in the
expression (i.e., DE loci).
A cut-off of 0.1 was used for DESeq (that was found very
conservative for small sample), while a cut off of 0.0001 was used
for both edgeR and DEGseq (both of them resulted to be more
permissive. Additionally, a threshold of 1.5 on the fold change
between the normalized samples was imposed to filter out those
genes whose significance appeared marginal (see File S1 for
details).
Finally, the results of each selection were cross-compared either
to compromise with their assumptions and to illustrate their
impact in the final choice.
DE evidence was finally classified as ‘‘strong’’, ‘‘good’’, and
‘‘acceptable’’. All DE genes below the fold-change threshold, but
found significant in at least one test, were classified as ‘‘weak’’
evidence. Figure 6A shows the scattered plot of the normalized log
intensities vs the normalized log ratio between the two samples for
RefSeq loci.
Supporting Information
Figure S1 Experimental procedure. Schematic representation of
the whole RNA-Seq experiment. Depicted are: Total RNA
isolation (1) and ribo-depletion (2). Ribo-depleted total RNA is
fragmented (3), then ligated to specific adaptors (4) and retro-
transcribed (5). The resulting cDNA is size selected by gel
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distribution is evaluated on Experion (8). Emulsion PCR is finally
used for the clonal amplification of SOLs (9). Enriched beads are
deposited onto glass slides (10), and sequenced by ligation on the
SOLiD v3 platform.
(JPG)
Figure S2 Data analysis pipeline. Schematic representation of
the data analysis workflow described in detail in ‘‘Materials and
Methods’’.
(JPG)
Figure S3 Summary of mapping results. Distribution of the
sequenced reads according to the mapping procedure. DS sample
(A) and Euploid (B).
(JPG)
Figure S4 Distribution of the UARs in the human genome.
Distribution of the UARs according to RefSeq genes, intronic
intergenic regions and mitochondrial chromosome. DS sample (A)
and Euploid (B).
(JPG)
Figure S5 Detection of alternative splicing events. Schematic
representation of the computational analysis used to detect
sample-specific ASEs both canonical and unannotated. Reliability
of the junction was measured with T1=3 (A) and with T1=5 (B).
(JPG)
Figure S6 Differential expression of lincRNAs. Standard MA-
plot of the normalized global observed counts per each lincRNA.
(JPG)
Figure S7 Quantitative Real-Time PCR validation. A random
selection of ‘‘no change’’ (A) and weak DE (B) RefSeq genes
between the analyzed samples confirmed by qRT-PCR. Relative
expression levels for a selection of DE RefSeq genes in DS state
(C).
(JPG)
Figure S8 Differential expression of igTARs and inTARs.
Standard MA-plot of the normalized global observed counts per
each identified igTAR (A) and inTAR (B). Venn diagrams showing
the number of regions with evidence of DE according to each
statistical method used (igTARs in panel C and inTARs in panel
D).
(JPG)
Table S1 Mapping summary.
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Table S2 Summary of mapping on the junctions.
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Table S3 Distribution of RPKM expression level of snoRNA
host genes.
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Table S4 List of differentially expressed snoRNAs in human
trisomy 21.
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Table S5 Primer pairs used for quantitative RT-PCR.
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File S1 Supporting Materials and Methods.
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